Education
About Us
Working with TipRanks
Follow Us
GNI Group Ltd. (DE:3G6)
FRANKFURT:3G6
3G6 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€8.80 - €26.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€914.36M
Enterprise Value€55.62B
Total Cash (Recent Filing)€9.93B
Total Debt (Recent Filing)¥6.62B
Price to Earnings (P/E)104.7
Beta1.60
Next Earnings
Aug 14, 2025EPS Estimate
0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding50,538,445
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)3.15
Price to Sales (P/S)0.00
P/FCF Ratio-42.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€22.21Price Target Upside24.78% Upside
Rating ConsensusHold
Number of Analyst Covering0
GNI Group News
PremiumCompany Announcements
GNI Group’s Cullgen Nears Nasdaq Listing After Shareholder ApprovalPremiumCompany Announcements
GNI Group’s Gyre Therapeutics Begins Phase 1 Trial for PAH Drug in China
PremiumCompany Announcements
GNI Group’s Gyre Pharmaceuticals Launches Etorel for Pulmonary Fibrosis
PremiumCompany Announcements
GNI Group’s Subsidiary Gyre Therapeutics Completes Successful Public Offering
PremiumCompany Announcements
GNI Group’s Liver Fibrosis Drug Achieves Key Trial Success in China
PremiumCompany Announcements
Gyre Therapeutics Launches $20 Million Public Stock Offering
PremiumCompany Announcements
GNI Group Reports Decline in Q1 FY2025 Financial Results
PremiumCompany Announcements
GNI Group Confirms NDA Timeline for HydronidoneOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.45%
Mutual Funds
― Other Institutional Investors
97.20% Public Companies and
Individual Investors
3G6 FAQ
What was GNI Group Ltd.’s price range in the past 12 months?
GNI Group Ltd. lowest stock price was €8.80 and its highest was €26.00 in the past 12 months.
What is GNI Group Ltd.’s market cap?
GNI Group Ltd.’s market cap is €914.36M.
When is GNI Group Ltd.’s upcoming earnings report date?
GNI Group Ltd.’s upcoming earnings report date is Aug 14, 2025 which is in 30 days.
How were GNI Group Ltd.’s earnings last quarter?
Currently, no data Available
Is GNI Group Ltd. overvalued?
According to Wall Street analysts GNI Group Ltd.’s price is currently Undervalued.
Does GNI Group Ltd. pay dividends?
GNI Group Ltd. does not currently pay dividends.
What is GNI Group Ltd.’s EPS estimate?
GNI Group Ltd.’s EPS estimate is 0.77.
How many shares outstanding does GNI Group Ltd. have?
GNI Group Ltd. has 50,538,445 shares outstanding.
What happened to GNI Group Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of GNI Group Ltd.?
Currently, no hedge funds are holding shares in DE:3G6
Company Description
GNI Group Ltd.
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.